A Phase 2 interventional study of ODM-109 and Placebo for ODM-109 in Amyotrophic Lateral Sclerosis, sponsored by Orion Corporation, Orion Pharma. Completed at 11 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-28.
Sponsored by Orion Corporation, Orion Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom — 15 open to participants now, 22 under way, 6 of them phase 3. Amyotrophic Lateral Sclerosis · United Kingdom.
Among the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom, this one is the 40th largest by enrollment of the 55 interventional ones that give a count, is one of 5 that started in 2015, is one of 14 in phase 2, and was the 15th registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →15 of the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom are open now. Recruiting first, the newest first:
The Leeds Teaching Hospitals NHS Trust · Sites in United Kingdom
Ages 18+ · Healthy volunteers
Trace Neuroscience, Inc. · Sites in United Kingdom, Germany, Netherlands
Ages 18–75
NHS Greater Glasgow and Clyde · Sites in United Kingdom
Ages 18+
Royal Brompton & Harefield NHS Foundation Trust · Sites in United Kingdom
Ages 18+
Prilenia · Sites in United Kingdom, United States, Belgium and 10 more countries
Ages 18–80
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 19 · Phase 3 25
First in 2003; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 227 across the 55 interventional studies, 73 across the 15 observational. Of the 45 that completed or were terminated, 21 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 70 have an industry lead sponsor. The 10 most frequent:
Orion Corporation, Orion Pharma is the lead sponsor of 101 studies on the registry; 3 are open to participants now.
Orion Corporation, Orion Pharma has 3 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
6 of the studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07818772NHS Greater Glasgow and Clyde7T Imaging Pilot-study in Patients With Motor Neuron Disease to Find Non-Invasive Disease Imaging Biomarkers | 2026-11-30 |
| NCT07393932University of SheffieldMND Together: Phase 1 | 2026-12 |
| NCT07943442The Leeds Teaching Hospitals NHS TrustNovel MRI for an Earlier Diagnosis of Motor Neurone Disease | 2027-05-31 |
| NCT07674667Trace Neuroscience, Inc.FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS | 2027-09 |
Add all 6 to your calendar (.ics) → With an account.
Among the 70 studies in Amyotrophic Lateral Sclerosis with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In the double-blind, cross-over part of the study, ODM-109 capsules and placebo capsules for ODM-109 will be administered for 2 weeks separated by a 19-23 days wash-out period. During each treatment period of the double-blind cross-over part, there will be a baseline visit (day 1) and 2 visits (5 ± 2 and 14 ± 2 days) after the start of study treatment. After completing the 3rd treatment period, the subjects will continue in the open-label follow-up part for 6 months. During the open-label follow-up, visits will be at 1, 3 and 6 months. An end-of-study visit will take place 14-25 days after the last study treatment administration for each subject. The study duration will be about 13-14 weeks for the double-blind cross-over part, and about 9-10 months for the entire study including the 6 months open-label follow-up.
The number of randomised study subjects is planned to be approximately 54 in cross-over comparison. The maximum number of subjects will not exceed 70.
Primary objective is to investigate the efficacy of oral ODM-109 on respiratory function in patients with amyotrophic lateral sclerosis (ALS).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ODM-109 capsules for oral administration
Drug: ODM-109 · Drug: Placebo for ODM-109
Placebo ODM-109 capsules for oral administration
Drug: ODM-109 · Drug: Placebo for ODM-109
ODM-109 1 mg capsule for oral administration.
Also known as: Levosimendan
Placebo capsule for oral administration.
Also known as: Placebo for Levosimendan
Slow vital capacity SVC
Pulmonary assessment
Time frame: 9 months
Hand grip strength and submaximal hand grip strength endurance
Assessment
Time frame: 3 months
Changes in subject's clinical condition (relative to the baseline/day 1 of the given treatment period) will be assessed using the Clinical Global Impression of Change (CGI-C)
Scales
Time frame: 3 months
Quality of life
Questionnaire
Time frame: 9 months
Revised ALS Functional Rating Scale ALSFRS-R
Scale
Time frame: 9 months
Oxygen saturation
Assessment
Time frame: 9 months
The concentrations of ODM-109, OR-1855 and OR-1896
Pharmacokinetics Blood samples.
Time frame: 3 months
Determination of subject's acetylation status
Pharmacogenomics Blood samples.
Time frame: 1 day (once at baseline)
Sniff nasal pressure SNP
SNP will be assessed in sitting position. SNP will be performed for 10 times. The highest value (cmH2O) measured will be the SNP variable.
Time frame: 9 months
Fatigue assessment
Visual analogue Scale VAS
Time frame: 3 months
Ran from Jul 2015 to primary completion in May 2017, 22 months.
Of 36 industry-sponsored phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 22 months is close to that.
Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Simendan
Amyotrophic Lateral Sclerosis →
Orion Corporation, Orion Pharma →